01 2Gowling Strathy & Henderson
02 7Gowling WLG (Canada) LLP
01 11340233
02 12113813
03 12226575
04 62519408
01 6OMALIZUMAB
02 3Omalizumab
01 3Powder for Solution
02 6SOLUTION
01 12012-08-14
02 12015-12-15
03 12016-07-23
04 62024-03-29
Patent Expiration Date : 2015-12-15
Date Granted : 1998-12-15
Brand Name : XOLAIR
Patent Number : 1340233
Filing Date : 1989-01-03
Strength per Unit : 150 mg / vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2015-12-15
Date Granted : 1998-12-15
Patent Expiration Date : 2012-08-14
Date Granted : 2005-04-12
Brand Name : XOLAIR
Patent Number : 2113813
Filing Date : 1992-08-14
Strength per Unit : 150 mg / vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2012-08-14
Date Granted : 2005-04-12
Patent Expiration Date : 2016-07-23
Date Granted : 2011-10-18
Brand Name : XOLAIR
Patent Number : 2226575
Filing Date : 1996-07-23
Strength per Unit : 150 mg / vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Subcutaneous
Patent Expiration Date : 2016-07-23
Date Granted : 2011-10-18
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 75 mg / 0.5 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 150 mg / 1 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 150 mg / 1.0 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 300 mg / 2.0 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 300 mg / 2.0 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Brand Name : XOLAIR
Patent Number : 2519408
Filing Date : 2004-03-29
Strength per Unit : 75 mg / 0.5 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2024-03-29
Date Granted : 2011-01-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
